Day: February 20, 2026

Kfar Saba, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the receipt of an additional order from a second branch at an Israeli defense entity for its advanced DefendAir™ multi-layered Counter-UAS (C-UAS) solution. This additional order builds on the Company’s successful first deployment with an Israeli defense entity earlier this year and underscores the growing trust in ParaZero’s innovative net-based interception technology. The new order includes:Specialized Launchers: High-precision net-launchers designed for rapid deployment in urban and field environments, enabling soft-kill interception of hostile...

Off The Hook YS Inc.Miami SupercenterStrategic move into physical global mega-destination site complements Off The Hook’s industry-leading AI-powered online marketplace, the largest of its kind for pre-owned boats in the U.S. Centralized hub to support the Company’s rapidly expanding inventory pipeline and international buyer network Wilmington, NC, Feb. 20, 2026 (GLOBE NEWSWIRE) — Off The Hook YS Inc. (NYSE American: OTH) (“Off The Hook Yachts” or “Off The Hook” or “the Company”), a vertically integrated, AI-powered marine marketplace, the largest buyer and seller of used boats in the nation, today announced it has signed a definitive agreement to acquire APEX, a premier South Florida marine service, storage, and sales organization. The acquisition is expected to close in 60 days pending customary due diligence. The transaction...

Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated mTNBC Patients VANCOUVER, Washington, Feb. 20, 2026 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”), today announced that new preclinical, translational, and clinical data supporting leronlimab’s proposed role in the treatment of metastatic triple-negative breast cancer was presented at the AACR Immuno-Oncology...

NEW YORK, NY,, Feb. 20, 2026 (GLOBE NEWSWIRE) — Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ: GFAI, GFAIW), an AI-driven technology company providing Agentic AI smart solutions in automation, robotics, and secured logistics, today announced that its Board of Directors has approved a Share Repurchase Program with authorization to purchase up to $5 million of the Company’s outstanding ordinary shares. This Program, effective immediately and in effect for up to one year from today, reflects the Company’s belief that its current market valuation does not fully reflect its intrinsic value, including the strength of its legacy secured logistics business and the long-term potential of its AI business.  The Program is intended to utilize disciplined capital allocation to help enhance this long-term value. “This share repurchase authorization reflects our confidence in the Company’s fundamentals,”...

HOUSTON, Feb. 20, 2026 (GLOBE NEWSWIRE) — Kirby Corporation (“Kirby”) (NYSE: KEX) today announced the appointment of Tracy A. Embree as a new independent member of the Kirby Board of Directors effective February 16, 2026. She will stand for election at the annual meeting of the corporation in April of this year. Ms. Embree is the retired President of Otis Americas, a division of Otis Worldwide Corporation, and brings more than 25 years of global leadership experience across industrial operations, manufacturing, distribution, and services businesses. Her extensive executive background and board experience further strengthen the depth and breadth of expertise on Kirby’s Board of Directors. Ms. Embree is an accomplished leader with extensive experience in power generation. Most recently, Ms. Embree served as President,...

Ottawa, ON, Feb. 20, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions, software, and robotics, today announced the appointment of Lieutenant-General (Ret’d) Michel Gauthier to its Military Advisory Board. The appointment comes as Canada advances its renewed Defence Industrial Strategy, a national framework focused on strengthening sovereign defence production, accelerating innovation, modernizing procurement, and reducing reliance on foreign supply chains. Lieutenant-General Gauthier brings more than 36 years of distinguished service with the Canadian Armed Forces. He served as Commander of the Canadian Expeditionary Force Command (CEFCOM), where he was responsible for operational command of Canadian Forces deployed internationally,...

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development,” please visit: https://ibn.fm/7N5vp Biotechnology mergers and acquisitions (“M&As”) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery...

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce that its executive team lead by Alex Black, Executive Chairman of the Board, and Andrew Cox, President & CEO, will attend BMO’s 35th Global Metals, Mining, and Critical Minerals Conference next week in Hollywood, Florida, to discuss its future growth plans for the Fenix Gold Mine and the newly acquired Condestable Mine. Rio2 is set to present on Wednesday, February 25, 2026, at 9:00 AM in Ballroom C. Please note that the BMO Conference is by invitation only. The presentation will be webcast (Live & On-Demand) through the following link https://app.webinar.net/JWR323Xo9g1  Additionally, Rio2 will be participating in this year’s PDAC. Andrew Cox is scheduled to present...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT’s clinical assets through Sarborg’s proprietary signature analysis and artificial intelligence capabilities. Sarborg’s business is built on the principle that biological, chemical and industrial signatures can function as a universal data language to identify, interpret and generate high-value opportunities. By analyzing, matching and learning from...

Regulatory clearance enables start of clinical testing and marks transition to clinical-stage company On track for initial clinical data to emerge from mid-2026Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company’s Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. Highlights:MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK Marks Zelluna’s transition from preclinical to clinical-stage...